Wall Street Zen Downgrades Henry Schein (NASDAQ:HSIC) to Hold

Henry Schein (NASDAQ:HSIC) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

A number of other research analysts also recently issued reports on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Wednesday. JPMorgan Chase & Co. decreased their target price on Henry Schein from $80.00 to $76.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Baird R W lowered Henry Schein from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 14th. Robert W. Baird reaffirmed a “neutral” rating and issued a $72.00 target price (down from $82.00) on shares of Henry Schein in a research report on Monday, July 14th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $78.00 target price on shares of Henry Schein in a research report on Tuesday, September 23rd. Five investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $76.67.

Henry Schein Stock Down 2.2%

Shares of NASDAQ:HSIC opened at $63.17 on Friday. The company has a market capitalization of $7.66 billion, a price-to-earnings ratio of 20.38, a P/E/G ratio of 2.13 and a beta of 0.81. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The business’s 50-day moving average is $67.48 and its 200-day moving average is $68.81. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.49.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.09). The business had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm’s revenue for the quarter was up 3.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.23 earnings per share. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. Equities research analysts predict that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Trading of Henry Schein

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HSIC. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc bought a new position in shares of Henry Schein in the second quarter valued at approximately $27,000. Rakuten Securities Inc. bought a new position in shares of Henry Schein in the first quarter valued at approximately $34,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Henry Schein in the second quarter valued at approximately $43,000. Finally, Steph & Co. bought a new position in shares of Henry Schein in the second quarter valued at approximately $44,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.